The field of precision cancer medicine is rapidly evolving, with an ever-growing list of targeted therapies approved for use in advanced cancer patients harboring specific genetic alterations. The Molecular Tumor Board is a robust and rapidly expanding clinical tumor sequencing program, which offers our patients the highest quality and most comprehensive genomic profiling test available.

In addition, the Duke Molecular Tumor Board provides molecular decision-making support to advance biomarker-based clinical research and to foster precision cancer medicine within the Duke Cancer Institute. Its members meet weekly and include a diverse group of pathologists, oncologists, scientists, medical geneticists, and clinical trial teams.

The Duke Molecular Tumor Board analyzes the results of clinical next-generation sequencing (NGS) tests and shares its insights with the patient’s care team. Discussions include clinical best practices, clinical recommendations based on specific mutational profiles, clinical trial matching, and referrals to medical genetics.

Molecular profiling data is kept in a secure registry maintained by the Duke Molecular Tumor Board, and updated recommendations are disseminated to patient care teams as clinical best practices evolve and novel therapeutic options emerge.